Gå direkt till innehåll

Nyhetsarkiv

  • SANOFI PASTEUR TO LICENSE MICRO-DELIVERY TECHNOLOGY

    Lyon, France – 21 December 2005 – Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has entered into an agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) to license the Micro-Delivery technology of BD Medical-Pharmaceutical Systems for use in the administration of sanofi pasteur’s human vaccine products. Läs resterande pressmeddelande i

  • SANOFI PASTEUR ANNOUNCES PRELIMINARY TRIAL RESULTS FOR A FIRST H5N1 PRE-PANDEMIC INFLUENZA VACCINE CANDIDATE WITH AN ADJUVANT

    Vice President Communications sanofi pasteur: Alain BERNAL – U. S. Media Relations: Len LAVENDA Tel.: +1 570 839 7187 - Fax: +1 570 839 0955 - Sanofi Pasteur Inc. - Discovery Drive - Swiftwater, PA 18370-0187 - USA - www.sanofipasteur.com ~ Data Show that the Vaccine Is Safe, Demonstrates Immunogenicity and Provides Future Direction For Development ~ Lyon, France – December 15, 2005 – Sano

  • INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE®-BASED REGIMENS WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN WOMEN WITH EARLY-STAGE HER2-POSITIVE BREAST CANCER

    Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen (“TCH”) with TAXOTERE® (docetaxel), the platinum salt carboplatin and HERCEPTIN® (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer Paris and San Antonio – December 8th, 2005 – The Breast Cancer International Research Group

  • FDA GRANTS PRIORITY REVIEW TO TAXOTERE FOR THE SUPPLEMENTAL NEW DRUG APPLICATION FOR ADVANCED GASTRIC CANCER

    Paris – December 2, 2005 – Sanofi-aventis announced today that the U.S Food and Drug Administration (FDA) has granted a six-month priority review for the supplemental new drug application (s-NDA) for Taxotere (docetaxel) Injection Concentrate, in combination with a current standard treatment (cisplatin and 5-fluorouracil) for advanced gastric cancer. The supplemental application is based on d

  • NEW ENGLAND JOURNAL OF MEDICINE PUBLICERAR RIO-LIPIDS-STUDIEN

    Studie visar att rimonabant signifikant reducerar kardiovaskulära och metabola riskfaktorer hos överviktiga och feta patienter Paris, Frankrike, 16 november 2005 – Sanofi-aventis tillkännagav att resultaten från RIO-Lipidsstudien publicerades i dag i The New England Journal of Medicine. I studien undersöktes effekten av rimonabant hos patienter med övervikt och fetma samt avvikande blodfetter (

  • INTERNATIONELL DIABETESUNDERSÖKNING BELYSER ATT PERSONER MED DIABETES OCH VÅRDGIVARE HAR OLIKA UPPFATTNINGAR OM SJUKDOMEN OCH HUR DEN SKA BEHANDLAS

    En stor undersökning som publiceras på World Diabetes Day 14 november 2005 visar att diabetiker i större utsträckning vill medverka vid beslut som rör behandlingen av sjukdomen. Paris, 14 november 2005 – Resultaten av en undersökning som publiceras idag på World Diabetes Day visar att nästan 80% av allmänheten personligen känner någon som har diabetes. För närvarande finns fler än 194 miljon

  • SANOFI PASTEUR SIGNS CONTRACT WITH FRENCH GOVERNMENT TO PRODUCE PANDEMIC INFLUENZA VACCINE

    Alain BERNAL Vice-President Corporate Communications Tel: + 33-(0)4-37-37-78-97 Fax: +33-(0)4-37-37-77 89 Len LAVENDA U.S. Media Relations Tel: +1-570-839-4446 Len.Lavenda@sanofipasteur.com ~ Influenza Vaccine Leader sanofi Pasteur Contributes to French Pandemic Preparedness ~ Lyon, France – November 10, 2005 – Following discussions which started a few months ago, sanofi pasteur,

  • APPOINTMENT OF JEAN-YVES WESSELY HEAD OF SANOFI-AVENTIS WINTHROP

    Paris – October 24, 2005- Effective october 2oo5, Jean-Yves Wessely is appointed Senior Vice President in charge of Winthrop, worldwide Generics Activities of sanofi-aventis, based in Paris. Jean-Yves Wessely, MD, brings with him a wealth of more than 25 years of experience in the pharmaceutical industry, as well as an intimate knowledge of Winthrop's key markets, having held several regional a

  • EXUBERA® INHALED INSULIN IMPROVES BLOOD SUGAR LEVELS IN ADULTS WITH TYPE 2 DIABETES BETTER THAN DIABETES PILLS ALONE 1

    Paris, 2005-10-20: Adults with type 2 diabetes taking Exubera (insulin human) alone or in combination with diabetes pills achieved significantly greater reductions in blood sugar levels compared to patients taking pills alone, according to a new study published in the October issue of Annals of Internal Medicine. Läs mer i bifogad fil. See attached document.

  • EXUBERA® RECEIVES POSITIVE OPINION FROM CHMP FOR THE TREATMENT OF TYPE 1 + TYPE 2 DIABETES

    Paris October 14, 2005 – Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of EXUBERA (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes. The proposed therapeutic indication for Exubera is for the treatment of adult pati

  • TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR

    MICROBIOLOGICAL ACTIVITY OF TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR TO OTHER STANDARD FIRST LINE ANTIBIOTICS OVER 4-YEAR PERIOD New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible Paris, 20 September 2005 – Data presented today at the 15th Annual Internati

  • TAXOTERE®-BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER

    INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER Interim analysis of more than 3,000 patients in BCIRG006 study also shows TAXOTERE® non-anthracycline-based chemotherapy combined with HERCEPTIN® improved disease-free surviv

Visa mer